ConductScience.org, home

Paper4134064

Activation of the alternate pathway of human complements by rabbit cells.

Platts-Mills TA and 1 other. J Immunol, 1974. Cited by 544 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Activation of the alternate pathway of human complements by rabbit cells. Papers, record 4134064. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4134064

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Activation of the alternate pathway of human complements by rabbit cells.
PubMed
Journal
J Immunol
PubMed
Year
1974
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
544
iCite
Relative citation ratio, by iCite
16.7
iCite
Revised in PubMed
2012-11-15
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Platts-Mills TAT A
2Ishizaka KK

Source PubMed

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Complement System ProteinsMajor topic
LymphocytesMajor topic
Acetates
Animals
Binding Sites, Antibody
Erythrocytes
Ethylenes
Glycols
Guinea Pigs
Hemadsorption
Hemagglutination Tests
Hemolysis
Humans
Immune Adherence Reaction
Iodine Radioisotopes
Protein Denaturation
Rabbits
Radioimmunoassay
Sheep
gamma-Globulins

Source PubMed

Cited by151

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 544 citations.

PMIDTitleJournalYearIn PapersSource
39,875,346Seventy Years Later: Systemic and Local Properdin in Atherosclerosis.J Am Heart Assoc2025https://conductscience.org/library/papers/39875346PubMed
38,638,432Cutting edge of genetically modified pigs targeting complement activation for xenotransplantation.Front Immunol2024https://conductscience.org/library/papers/38638432PubMed
37,817,009Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD.Ann Hematol2023https://conductscience.org/library/papers/37817009PubMed
37,662,914Properdin inhibition ameliorates hepatic ischemia/reperfusion injury without interfering with liver regeneration in mice.Front Immunol2023https://conductscience.org/library/papers/37662914PubMed
36,330,514Pitfalls in complement analysis: A systematic literature review of assessing complement activation.Front Immunol2022https://conductscience.org/library/papers/36330514PubMed
35,493,497Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside.Front Immunol2022https://conductscience.org/library/papers/35493497PubMed
35,387,017Lessons in Innate and Allergic Immunity From Dust Mite Feces and Tick Bites.Front Allergy2021https://conductscience.org/library/papers/35387017PubMed
33,847,933Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.Methods Mol Biol2021https://conductscience.org/library/papers/33847933PubMed
33,847,931Sheep Erythrocyte Preparation for Hemolytic Tests Exploring Complement Functional Activities.Methods Mol Biol2021https://conductscience.org/library/papers/33847931PubMed
33,006,965Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease.PLoS Comput Biol2020https://conductscience.org/library/papers/33006965PubMed
31,787,968Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics.Front Immunol2019https://conductscience.org/library/papers/31787968PubMed
31,405,955Underlying Glycans Determine the Ability of Sialylated Lipooligosaccharide To Protect Nontypeable Haemophilus influenzae from Serum IgM and Complement.Infect Immun2019https://conductscience.org/library/papers/31405955PubMed
31,157,175Suppression of Alternative Lipooligosaccharide Glycosyltransferase Activity by UDP-Galactose Epimerase Enhances Murine Lung Infection and Evasion of Serum IgM.Front Cell Infect Microbiol2019https://conductscience.org/library/papers/31157175PubMed
30,405,598Interpretation of Serological Complement Biomarkers in Disease.Front Immunol2018https://conductscience.org/library/papers/30405598PubMed
27,799,929The High Prevalence of Functional Complement Defects Induced by Chemotherapy.Front Immunol2016https://conductscience.org/library/papers/27799929PubMed
25,841,549Anaphylaxis to the carbohydrate side chain alpha-gal.Immunol Allergy Clin North Am2015https://conductscience.org/library/papers/25841549PubMed
24,194,425Complement lesions in cell membranes from joint effusions of various types of arthritis.Inflammation1976https://conductscience.org/library/papers/24194425PubMed
23,227,092Complement diagnostics: concepts, indications, and practical guidelines.Clin Dev Immunol2012https://conductscience.org/library/papers/23227092PubMed
23,137,394Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating.Biomaterials2013https://conductscience.org/library/papers/23137394PubMed
22,414,497Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis media.Microbes Infect2012https://conductscience.org/library/papers/22414497PubMed

See all 151 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4134064

GET https://conductscience.org/api/papers/v1/4134064/cited_by?page=2